These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39615893)

  • 1. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC.
    Li H; Liu J; Zhang L; Xu Y; Wang X; Lan S; Cui P; Wang G; Cai S; Cheng Y
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39615893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Tanaka H; Makiguchi T; Tozuka T; Kawashima Y; Oba T; Tsugitomi R; Koyama J; Tambo Y; Ogusu S; Saiki M; Gyotoku H; Hasegawa T; Miyauchi E; Sonoda T; Saito R; Nakatomi K; Sakatani T; Kudo K; Tsuchiya-Kawano Y; Nishio M
    Eur J Cancer; 2024 Dec; 213():115117. PubMed ID: 39522333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.
    Formica V; Morelli C; Fornaro L; Riondino S; Rofei M; Fontana E; Smyth EC; Roselli M; Arkenau HT
    ESMO Open; 2024 Nov; 9(11):103967. PubMed ID: 39541621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the PD-L1 Paradigm: A Comprehensive Systematic Review and Meta-Analysis of Scoring Systems and Additional Biomarkers Influencing Immune Checkpoint Inhibitor Outcomes in Breast Cancer.
    Mo S; Wang Y; Wang Y; Chen X; Zhu H; Zou Z; Xiao W
    Cancer Control; 2024; 31():10732748241299074. PubMed ID: 39571079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).
    Landre T; Chouaïd C; Sadaoui N; Bouharati D; Taleb C
    J Chemother; 2024 Dec; 36(8):675-681. PubMed ID: 38303601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D
    Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    Elkrief A; Montesion M; Sivakumar S; Hale C; Bowman AS; Begüm Bektaş A; Bradic M; Kang W; Chan E; Gogia P; Manova-Todorova K; Mata DA; Egger JV; Rizvi H; Socci ND; Kelly DW; Rosiek E; Meng F; Tam G; Fan N; Drilon A; Yu HA; Riely GJ; Rekhtman N; Quintanal Villalonga Á; Dogan S; Bhanot U; Gönen M; Loomis B; Hellmann MD; Schoenfeld AJ; Ladanyi M; Rudin CM; Vanderbilt CM
    J Clin Oncol; 2024 Oct; 42(28):3339-3349. PubMed ID: 39038258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
    Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Wang Z; Liu H; Zhang W
    J Immunother; 2025 Jan; 48(1):18-26. PubMed ID: 38800996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
    Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
    Miller S; Jiang R; Schipper M; Fritsche LG; Strohbehn G; Wallace B; Brinzevich D; Falvello V; McMahon BH; Zamora-Resendiz R; Ramnath N; Dai X; Sankar K; Edwards DM; Allen SG; Yoo S; Crivelli S; Green MD; Bryant AK
    Lancet Oncol; 2024 Dec; 25(12):1666-1676. PubMed ID: 39551068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: A real-world retrospective study.
    Chen L; Zhou H; Wu H; Lu Q; Huang J; Wang S
    Int Immunopharmacol; 2024 Dec; 143(Pt 3):113516. PubMed ID: 39515042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.
    Tsuruoka K; Tamura Y; Shimazu Y; Arai M; Mitsuya S; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Ikeda S; Kawabata S; Imagawa A; Fujisaka Y
    Anticancer Res; 2024 Dec; 44(12):5531-5539. PubMed ID: 39626945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups.
    Leone AG; Mai AS; Fong KY; Yap DWT; Kato K; Smyth E; Moehler M; Seong JTC; Sundar R; Zhao JJ; Pietrantonio F
    ESMO Open; 2024 Nov; 9(11):103962. PubMed ID: 39426081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of Tongfu Lifei decoction inhibiting the programmed death-1/programmed death-ligand 1 signaling pathway in THP-1 cells by regulating microRNA-146a].
    Lyu B; Li L; Huang R; Zhou X; Han L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 Oct; 36(10):1038-1043. PubMed ID: 39586721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
    Liu M; Li Q; Meng X; Cui Y; Sun W; Wang H; Gao Q
    Medicine (Baltimore); 2024 Dec; 103(49):e40569. PubMed ID: 39654181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.